Crucell and DSM Announce PER.C6® Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production

13-Aug-2004 - Leiden/Sittard, The Netherlands. Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM Biologics announced that Crucell has signed a PER.C6® research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6® technology in research ...

Geron Announces Publication Showing In Vivo Efficacy Of An Oncolytic Virus Containing The Telomerase Promoter

13-Aug-2004 - Menlo Park. Geron Corporationannounced the publication of research demonstrating selectivity, efficacy and lack of toxicity of an oncolytic virus containing the human telomerase promoter. The work was published in the August issue of Cancer Gene Therapy by scientists from Genetic Therapy, Inc. ...

AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents

12-Aug-2004 - Portland. AVI BioPharma, Inc. announced it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The five-year agreement provides for testing of AVI's NeuGene® antisense therapeutics against several ...

Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research

Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million

12-Aug-2004 - Vernalis plc announces that the Novartis Institutes for BioMedical Research, Inc., (Novartis) has exercised its option to license exclusive worldwide rights to Vernalis' lead oncology research programme on Hsp90. Today's announcement is the positive conclusion of the option agreement the ...

VCU Expert in New England Journal of Medicine Article Calls for Urgent Response to Antibiotic Shortage

Article Cites Obstacles to Antibiotic Research

11-Aug-2004 - Richmond. Scientists, the federal government and the pharmaceutical industry must work together quickly to solve the growing crisis of antibiotic-resistant bacteria, a Virginia Commonwealth University infectious disease expert said in today's issue of The New England Journal of Medicine. Money ...

IBM and Cellomics Create Affordable Technology Solution to Accelerate Cell-Based Drug Discovery

First High-Content Screening and Analysis Solution Being Used by Bio-Pharmaceutical Researchers at EPOPLUS to Identify Off-Target Effects in Live Cells

11-Aug-2004 - Somers and Pittsburgh. IBM and Cellomics, Inc., a leader in creating software and hardware tools for High Content Screening (HCS), today announced they have launched a customized information technology (IT) solution that allows biopharmaceutical scientists and academic researchers to better ...

Cobra authorised to manufacture broad range of biopharmaceuticals for European Clinical trials

10-Aug-2004 - Cobra Biomanufacturing Plc announced that it has received a Manufacturer's Authorisation - Investigational Medicinal Products, (MA(IMP)), from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its clinical trials manufacturing facilities in both Keele and Oxford. This ...

YM BioSciences' EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner

10-Aug-2004 - Mississauga. YM BioSciences Inc., the cancer drug development company with an advanced-stage portfolio, and its majority-owned subsidiary, CIMYM Inc., announced that their anti-cancer drug TheraCIM hR3 has been designated an Orphan Drug by the European Medicines Agency for the Evaluation of ...

ClinPhone Invests in IT Infrastructure to Make Customer Clinical Trial Data Ultra Secure

09-Aug-2004 - ClinPhone, the global leader in clinical trial management solutions, is embarking on a 9 month project to overhaul its IT subsystems in order to make its customers' data even more secure and reliable. By investing in a state-of-the-art storage and backup software platform from IBM, and by ...

Hybridon Licenses Key VEGF Patents to Alnylam for Treatment of Ocular Diseases with RNAi Therapeutics

05-Aug-2004 - Alnylam Pharmaceuticals, Inc. and Hybridon, Inc. ( announced that they have entered into an agreement providing Alnylam with an exclusive license to Hybridon's rights to target Vascular Endothelial Growth Factor (VEGF) for ocular indications with RNA interference molecules (RNAi). Hybridon has a ...